FDA批准Lupin的生物相似的Armlupeg 来降低化疗病人的感染风险。 FDA approves Lupin’s biosimilar Armlupeg to reduce infection risk in chemo patients.

美国林业发展局已经批准Lupin的生物类药物Armlupeg(pegfilgrastim-unne), 用于降低接受化疗的癌症患者, 特别是非细胞恶性肿瘤患者的感染风险。 The U.S. FDA has approved Lupin’s biosimilar drug Armlupeg (pegfilgrastim-unne) for reducing infection risk in cancer patients undergoing chemotherapy, specifically those with non-myeloid malignancies. 这种6mg/ 0.6ml的皮下注射剂由Lupin在普那的工厂制造,经过FDA检查,旨在治疗中性质减退和发烧性中性质减退. The 6 mg/0.6 mL subcutaneous injection, manufactured at Lupin’s Pune facility inspected by the FDA, aims to treat neutropenia and febrile neutropenia. 批准支持Lupin在美国扩大可负担的生物类似药的推动力,其中参考药物菲拉斯蒂姆在2025年9月之前的估计年销售额为1295亿美元. The approval supports Lupin’s push to expand affordable biosimilars in the U.S., where the reference drug pegfilgrastim had $1.295 billion in estimated annual sales through September 2025.